A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

NCT07188896 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Advanced Renal Cell Carcinoma (aRCC)
Metastatic Renal Cell Carcinoma ( mRCC)
Clear Cell Renal Cell Carcinoma (ccRCC)

Interventions

DRUG: Fianlimab
DRUG: Ipilimumab
DRUG: Nivolumab
DRUG: Cemiplimab

Sponsor

Brian Rini

Collaborators

[object Object]
[object Object]